Claudia Scherl1, Marlen Haderlein2, Abbas Agaimy3, Konstantinos Mantsopoulos4, Michael Koch4, Maximilian Traxdorf4, Rainer Fietkau2, Philipp Grundtner4, Heinrich Iro4. 1. Department of Otolaryngology, Head and Neck Surgery, Friedrich-Alexander-University (FAU), Waldstraße 1, 91054, Erlangen, Germany. claudia.scherl@umm.de. 2. Department of Radiation Oncology, Friedrich-Alexander-University (FAU), Universitätsstraße 27, 91054, Erlangen, Germany. 3. Department of Pathology, Friedrich-Alexander-University (FAU), Krankenhausstraße 8-10, 91054, Erlangen, Germany. 4. Department of Otolaryngology, Head and Neck Surgery, Friedrich-Alexander-University (FAU), Waldstraße 1, 91054, Erlangen, Germany.
Abstract
PURPOSE: To determine survival and management strategies for high-grade adenocarcinoma of salivary glands (ASG). METHODS: A retrospective analysis of cases diagnosed between 1998 and 2015 from our single tertiary referral center was performed. Multivariable logistic regression was used to determine factors associated with survival. RESULTS: Thirty-eight cases of high-grade ASG were identified. Most patients were men (68.4%) with a median age of 65.5 years (range 23-84 years). Most tumors were T3 and T4 (65.8%). Regional metastases were common (55.2%), and 42.1% developed distant metastases. The mean follow-up was 60.5 months. All patients received surgery as primary treatment, with 84.2% of patients receiving adjuvant radiation therapy or chemoradiotherapy ([C]RT). Cumulative overall survival was 89.1%, 50.9%, and 20.7% after 1, 5, and 10 years, respectively. Disease-specific survival was 94.4%, 69.8%, and 42.8%, and distant-metastases-free survival (DMFS) was 80.5%, 50.1%, and 40.1% after 1, 5, and 10 years. On multivariable analysis, advanced T status correlated with DMFS (hazard ratio 2.75, 95% CI 0.93-8.16). Postsurgical (C)RT reduced the locoregional recurrence rate by 23.9%, and it improved the locoregional-recurrence-free survival by 39% (p = 0.094). CONCLUSION: High-grade ASG is considered to have an unfavorable prognosis. Adjuvant (C)RT reduces the rate of locoregional recurrences. Distant metastases are common, and an advanced T stage has increased prognostic value for development of early distant lesions.
PURPOSE: To determine survival and management strategies for high-grade adenocarcinoma of salivary glands (ASG). METHODS: A retrospective analysis of cases diagnosed between 1998 and 2015 from our single tertiary referral center was performed. Multivariable logistic regression was used to determine factors associated with survival. RESULTS: Thirty-eight cases of high-grade ASG were identified. Most patients were men (68.4%) with a median age of 65.5 years (range 23-84 years). Most tumors were T3 and T4 (65.8%). Regional metastases were common (55.2%), and 42.1% developed distant metastases. The mean follow-up was 60.5 months. All patients received surgery as primary treatment, with 84.2% of patients receiving adjuvant radiation therapy or chemoradiotherapy ([C]RT). Cumulative overall survival was 89.1%, 50.9%, and 20.7% after 1, 5, and 10 years, respectively. Disease-specific survival was 94.4%, 69.8%, and 42.8%, and distant-metastases-free survival (DMFS) was 80.5%, 50.1%, and 40.1% after 1, 5, and 10 years. On multivariable analysis, advanced T status correlated with DMFS (hazard ratio 2.75, 95% CI 0.93-8.16). Postsurgical (C)RT reduced the locoregional recurrence rate by 23.9%, and it improved the locoregional-recurrence-free survival by 39% (p = 0.094). CONCLUSION: High-grade ASG is considered to have an unfavorable prognosis. Adjuvant (C)RT reduces the rate of locoregional recurrences. Distant metastases are common, and an advanced T stage has increased prognostic value for development of early distant lesions.
Entities:
Keywords:
Head and neck cancer; Salivary gland cancer; Salivary gland malignancy; Survival salivary gland cancer; Treatment salivary gland cancer
Authors: Vincent Vander Poorten; Patrick J Bradley; Robert P Takes; Alessandra Rinaldo; Julia A Woolgar; Alfio Ferlito Journal: Head Neck Date: 2011-05-25 Impact factor: 3.147
Authors: Peter P Luk; Jared D Weston; Bing Yu; Christina I Selinger; Rafael Ekmejian; Timothy J Eviston; Trina Lum; Kan Gao; Michael Boyer; Sandra A O'Toole; Jonathan R Clark; Ruta Gupta Journal: Head Neck Date: 2015-12-24 Impact factor: 3.147
Authors: Boban M Erovic; Manish D Shah; Guillem Bruch; Meredith Johnston; U Johnston; John Kim; Brian O'Sullivan; Bayardo Perez-Ordonez; Ilan Weinreb; Eshetu G Atenafu; John R de Almeida; Patrick J Gullane; Dale Brown; Ralph W Gilbert; Jonathan C Irish; David P Goldstein Journal: J Otolaryngol Head Neck Surg Date: 2015-10-29
Authors: Michał Żurek; Kamil Jasak; Karolina Jaros; Piotr Daniel; Kazimierz Niemczyk; Anna Rzepakowska Journal: Int J Environ Res Public Health Date: 2022-08-18 Impact factor: 4.614